Article Text
Abstract
Background There is an urgent need to identify novel biomarkers for lupus nephritis (LN) in disease diagnosis, assessment, monitoring, and prognosis prediction. Here, we report a new non-invasive urinary biomarker, L-selectin, in two independent multiple-ethnicity SLE cohorts from three centers.
Methods Urinary L-selectin (uL-selectin) was tested cross-sectionally in a Chinese-based cohort (n=255) and a US-based cohort (n=223) of SLE patients and controls using ELISA. A longitudinal cohort includes eighteen active Chinese LN patients who were followed up for a minimum of 6 months.
Results In the Chinese cross-sectional cohort, uL-selectin was significantly increased in active lupus nephritis (aLN) patients compared with active non-renal SLE patients (aNR), inactive LN patients (iLN), inactive non-renal SLE patients, chronic kidney disease (CKD) patients, and healthy controls (HC) (all p < 0.0001) (table 1, figure 1A). uL-selectin positively correlated with global and renal disease activities (all p < 0.0001) and was significantly associated with activity index (AI) and chronicity index (CI) (figure 1E-F). It also correlated with conventional metrics (serum C3, anti-dsDNA and 24h proteinuria) and histological characteristics (figure 1G). Univariate and multivariate logistic regression analyses revealed low uL-selectin as an independent risk factor for high CI (CI>3) (figure 1J). Similar results were noted in the US-based cohort consisting of Caucasian, African American and Hispanic subjects (figure 1B-D). In a longitudinal cohort of LN patients, uL-selectin levels decreased at the end of follow up in the remission group (p=0.001), but not in non-remission patients (p=0.58) (figure 1H-I).
Conclusions uL-selectin is a novel biomarker of clinical disease activity and renal histopathology in LN across multiple ethnicities. It also reflects treatment response in LN patients during follow up.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.